Bowel obstruction is a common and distressing outcome in patients with abdominal or pelvic cancer. Although surgery should be the primary treatment for malignant obstruction, it is now recognized that some patients with advanced disease or in generally poor condition are unfit for surgery and require alternative management to relieve distressing symptoms. A number of treatment options are now available for the patient with advanced and terminal cancer who develops intestinal obstruction. Medical measures such as analgesics, anti-secretory drugs and antiemetics may be used alone or in combination to relieve symptoms.
RipamontiC., TwycrossR., BainesM., BozzettiF., CapriS., De ConnoF., GemloB., HuntT.M., KrebsH.B., MercadanteS., SchaererR., WilkinsonP.: Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer, 19: 23–34, 2001.
2.
FeuerD.J., BroadleyK.E., ShepherdJ.H., BartonD.P.J.: Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. Gynecol Oncol, 75: 313–322, 1999.
3.
RipamontiC., MercadanteS.: Pathophysiology and management of malignant bowel obstruction. In: Oxford textbook of palliative medicine, 3rd edn, DoyleD., HanksG.W., McDonaldN., ChernyN. (Eds), pp 496–506, Oxford University Press, New York, 2004.
4.
BainesM., OliverD.J., CarterR.L.: Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study. Lancet, 2: 990–993, 1985.
5.
FainsingerR.L., SpachynskiK., HansonJ.: Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symp Manag, 9: 12–18, 1994.
6.
World Health Organization:Cancer pain relief.Geneva, Switzerland, World Health Organization, 1986.
7.
MercadanteS., SapioM., SerrettaR.: Treatment of pain in chronic bowel subobstruction with self-administration of methadone. Support Care Cancer, 5: 327–329, 1997.
8.
MercadanteS., CasuccioA., FulfaroF., GroffL., BoffiR., VillariP.: Switching from morphine to metadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol, 19: 2898–2904, 2001.
9.
RipamontiC., PanzeriC., GroffL., GaleazziG., BoffiR.: The role of somatostatin and octreotide in bowel obstruction: preclinical and clinical results. Tumori, 87: 1–9, 2001.
10.
RipamontiC., MercadanteS.: How to use octreotide for malignant bowel obstruction. J Support Oncol, 2: 1–8, 2004. www.SupportiveOncology.net
11.
NellgardP., BojoL., CassutoJ.: Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction. Scan J Gastroenterol, 30: 464–469, 1995.
12.
FallonM.T.: The physiology of somatostatin and its synthetic analogue, octreotide. Eur J Palliat Care, 1: 20–22, 1994.
13.
MercadanteS.: Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symp Manag, 16: 278–279, 1998.
14.
RipamontiC., MercadanteS., GroffL., ZeccaE., De ConnoF., CasuccioA.: Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction having a nasogastric tube. A prospective, randomized clinical trial. J Pain Symp Manag, 19: 23–34, 2000.
15.
MercadanteS., RipamontiC., CasuccioA., ZeccaE., GroffL.: Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer, 8: 188–191, 2000.
16.
MystakidouK., TsilikaE., KalaidopoulouO., ChondrosK., GeorgakiS., PapadimitriouL.: Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res, 22: 1187–1192, 2002.
17.
MercadanteS., AvolaG., MaddaloniS., SalamoneG., AragonaF., RodolicoV.: Octreotide prevents the pathological alterations of bowel obstruction in cancer patients. Support Care Cancer, 4: 393–394, 1996.
FainsingerR.L., MacEachernT., MillerM.J.: The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symp Manag, 9: 298–302, 1994.
21.
FainsingerR.L.: Hydration. In: Gastrointestinal symptoms in advanced cancer patients, RipamontiC., BrueraE. (Eds), vol 22, pp 395–410, Oxford University Press, Oxford, 2002.
